Sign In
Buy OGEN
$0.610
+0 (+0%)
At Close: Jun 03, 2026
Oragenics, Inc. Announces Pricing of Public Offering
08:30am, Tuesday, 25'th Jun 2024
SARASOTA, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders,
Oragenics, Inc. Announces Proposed Public Offering
06:43pm, Monday, 24'th Jun 2024
SARASOTA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal pharmaceuticals for the treatm
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer
08:00am, Wednesday, 22'nd May 2024
Dr. Peacock to Oversee Upcoming Phase II Clinical Trial for Treating Concussion in the Emergency Department Dr. Peacock to Oversee Upcoming Phase II Clinical Trial for Treating Concussion in the Emerg
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
08:00am, Friday, 17'th May 2024
SARASOTA, Fla., May 17, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today anno
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
05:50pm, Friday, 19'th Apr 2024
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
07:00am, Monday, 18'th Mar 2024
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
07:45am, Tuesday, 05'th Mar 2024
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced
Oragenics Announces Closing of Public Offering
04:04pm, Friday, 01'st Mar 2024
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the t
Why Is Oragenics (OGEN) Stock Down 45% Today?
08:29am, Wednesday, 28'th Feb 2024
Oragenics (NYSEMKT: OGEN ) stock is falling on Wednesday after the antibiotics development company announced details of a public offering for its shares. Oragenics is selling 1.4 million shares of
Oragenics Announces Pricing of Public Offering
09:25pm, Tuesday, 27'th Feb 2024
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the t
Oragenics Announces Proposed Public Offering
04:33pm, Tuesday, 27'th Feb 2024
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the t
Oragenics, Inc. Announces Leadership Transition
04:41pm, Monday, 12'th Feb 2024
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurolo
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
08:00am, Wednesday, 07'th Feb 2024
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, tod
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
08:00am, Monday, 05'th Feb 2024
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, tod
Oragenics Announces Termination of At-The-Market Offering Program
05:34pm, Tuesday, 23'rd Jan 2024
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has terminated its previously announced “at-the-market” (“ATM”) eq
